⌕
Sionna Therapeutics Inc. · SION · Nasdaq
Tenet 74 · Solid
⇄ Compare
$5.12+0.02 (+0.30%)
Market open · 15-min delayed · as of 10:48 AM ET

Sionna Therapeutics Inc. · Overview

Industry: Pharmaceutical Preparations · see every company filed here →

Sionna Therapeutics Inc. scores 74/100. Solid. Strongest on value and financial health, quality is the soft spot versus 400 Healthcare peers. Insufficient inputs: Tenet 74 is built from 3 of 4 pillars, from 30% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=400
74/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
97
Quality
30
Health
94
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueA+QualityDHealthAGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
no P/E on file
P/B
0.9×
cap ÷ Jun 30, 2026 book value, Oct 1, 2026 close
P/S
—
no P/S on file
ROE
−32%
TTM through Jun 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
no net margin on file
Current ratio
20.05
Jun 30, 2026 balance sheet
Net debt / EBITDA
—
negative EBITDA denominator
EPS CAGR 3y
—
needs five years of positive earnings
Market cap
$230.0M
small cap
Div yield
0.00%
reinvests all
52-wk range
4.01 – 54.97
low → high

Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).

The whole report, at a glance · every card is a live peek, click any to open the section

Tenets
1 / 17
  • ✕ Piotroski F-Score
  • ✕ Graham Defensive
  • ✕ Drawdown Context
  • ✕ Reversal Evidence
  • ✓ Not-a-Value-Trap Gate
  • ✕ Quality Floor
+11 more →
Financials
Revenue, margins and the five-year statements.
Analyst Forecasts
Consensus estimates are on the Analyst tab.
Earnings
TBA
next report
Beat/miss history appears here after the first tracked report.
Statistics
ROIC−41%
Technical Analysis
Downtrend short-term signal
vs 50-day−68.3%
vs 200-day−85.0%
RSI (14)28
News & Insights
Headlines are on the News tab.
Dividends
0.00% yield

Pays no dividend. Every dollar of profit is reinvested into the business.

Ownership
158 13F filers

Holdings are on file. The share count they would be divided by is unverified, so the percentage is withheld.

About Sionna Therapeutics Inc.

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance reg…

Composite computed 2026-10-02 · peer basis: Healthcare (n=400) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

Free account: the funds that hold SION, and at what weight. Everything else on this page stays open.Create a free account
Methodology© 2026 Tenet Investing Inc. · Toronto, Canada

Data from Intrinio and Financial Modeling Prep.